• All
  • Cloud
    • Solutions
    • Virtualization
  • Data
    • Analytics
    • Big Data
    • Customer Data Platform
  • Digital
    • Digital Marketing
    • Social Media Marketing
  • Finance
    • Risk & Compliance
  • Human Resources
    • HR Solutions
    • Talent Management
  • IT Infra
    • App Management Solutions
    • Best Practices
    • Datacenter Solutions
    • Infra Solutions
    • Networking
    • Storage
    • Unified Communication
  • Mobility
  • Sales & Marketing
    • Customer Relationship Management
    • Sales Enablement
  • Security
  • Tech
    • Artificial Intelligence
    • Augmented Reality
    • Blockchain
    • Chatbots
    • Internet of Things
    • Machine Learning
    • Virtual Reality
  • All
  • Cloud
    • Solutions
    • Virtualization
  • Data
    • Analytics
    • Big Data
    • Customer Data Platform
  • Digital
    • Digital Marketing
    • Social Media Marketing
  • Finance
    • Cost Management
    • Risk & Compliance
  • Human Resources
    • HR Solutions
    • Talent Management
  • IT Infra
    • App Management Solutions
    • Best Practices
    • Datacenter Solutions
    • Infra Solutions
    • Networking
    • Storage
    • Unified Communication
  • Mobility
  • Sales & Marketing
    • Customer Relationship Management
    • Sales Enablement
  • Security
  • Tech
    • Artificial Intelligence
    • Augmented Reality
    • Blockchain
    • Chatbots
    • Internet of Things
    • Machine Learning
    • Virtual Reality
  • All
  • Finance
  • IT Infra
    • Networking
  • Tech
    • Augmented Reality
The Rising Usage of GLP-1 Medications for Obesity and What It Will Cost You

The Rising Usage of GLP-1 Medications for Obesity and What It Will Cost You

Calibrate
Published by: Research Desk Released: Sep 28, 2022

Understanding the inevitable increase in obesity medication utilization Obesity is the largest category of chronic disease and a major driver of healthcare costs. Over 40% of Americans are living with obesity, and this number forecasted to be closer to 50% by 2030—making it apparent that this growing healthcare crisis requires immediate action.

Despite the gravity of the obesity epidemic, legacy obesity treatments have either failed to produce effective results, or have failed to be widely adopted. GLP-1s were originally created for diabetes, but are now indicated for obesity treatment. Given their efficacy and the size of the addressable market, GLP-1 medications are set to become the next blockbuster pharma category, with a projection of $70B in sales by 2030. Download the eBook to learn about the inevitable increase in obesity medication utilization, and how you can control the associated costs for your organization